TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04471012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual counselling program
Description: An individual counseling program that was based on TM and included motivational interview techniques was given to the experimental group which involved general information about the importance of weight control, healthy diet, and exercise.~Benefits of Healthy Diet and Physical Activity in PCOS Training Booklet was given during their first counseling session.
Study: NCT02733588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pump™ (glucagon infusion)
Description: 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
Study: NCT02999854

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATIR101
Description: ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
Study: NCT00622089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 150mg DIO-902 + 10mg atorvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 300mg dose once per day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIO-902
Description: 450mg dose once per day for 24 weeks
Study: NCT05878756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Strength Training
Description: In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Strength Training
Description: In addition to conventional therapy, experimental group was also given functional strength training program. Functional strength training was given as home program consisting of ten tasks.The ten tasks were STS, one leg standing, weight shifting(from one side of body to other), step-ups, lateral step-ups, squatting against wall, picking an object from standing position, walking forward, walking backward and kicking the ball.
Study: NCT00929188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
Study: NCT01632228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Study: NCT00359333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine , Docetaxel
Description: Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
Study: NCT03488888

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline 0,9%
Description: Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
Study: NCT02982317

Intervention type: PROCEDURE
Intervention: Manual palpation identification lumbar spine

Intervention type: PROCEDURE
Intervention: Automated ultrasound technology identification
Description: This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine

Intervention type: PROCEDURE
Intervention: Lumbar level identification gold standard ultrasound
Study: NCT04894643

Intervention type: RADIATION
Group type: OTHER
Intervention: Proton Ions
Description: According to the radiation plan (between 50.4 and a maximum of 60.2 Gy) after Chemotherapy with Nab-PACLitaxel (Abraxane®) + Gemcitabine and concomitant to Capecitabine.

Intervention type: DRUG
Group type: OTHER
Intervention: Nab-PACLitaxel
Description: Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~It will be administered as intra venous infusion over 30 minutes.
Study: NCT02445352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
Study: NCT04894643

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy will be delivered upfront for three cycles (week 2-4, week 6-8 and week 10-12) with combined Nab-PACLitaxel (Abraxane®) and Gemcitabine Therapy.~Gemcitabine will also be administered as intra venous infusion over 30 minutes immediately after Nab-PACLitaxel.

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: Concomitant to proton-radiotherapy (on the same days, within week 14-19)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical resection of the pancreas (when feasible)
Description: Pre surgical re-evaluation will be performed at week 21 after enrollment. Patients fulfilling surgery-entry criteria, which consist of no distant metastasis, no massive ascites, no massive pleural effusion, no serious infection, no serious, unresolved chemoradiotherapy related, adverse events and adequate organ system function, will undergo surgery on week 22 (± 1 week). This should be performed via laparotomy.
Study: NCT00991328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SctO2 < 60 %.
Description: The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
Study: NCT00442832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1792
Description: TD-1792 2 mg/kg/day IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1 Gm IV q 12 hrs
Study: NCT01571908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium perfusion
Description: The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo perfusion
Description: The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
Study: NCT03040414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedtronicMinimed 670G 3.0 hybrid closed loop system
Description: The components of the intervention are the insulin pump with insulin delivery algorithm (PID).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
Description: The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
Study: NCT02337972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone-iodine 4%
Description: Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
Study: NCT01498627

Intervention type: BIOLOGICAL
Intervention: Cervarix
Description: 3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).

Intervention type: BIOLOGICAL
Intervention: Cervarix
Description: 3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).

Intervention type: OTHER
Intervention: Data collection
Description: PGRx information system
Study: NCT02445352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Study: NCT01498627

Intervention type: OTHER
Intervention: Data collection
Description: PGRx information system
Study: NCT00771732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: 6 minute light therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: light therapy
Description: combination of wavelengths
Study: NCT01740479

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Revascularization Strategy
Description: Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
Study: NCT02931604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSafe Medical Device for Maxillary Sinus
Description: Sinus lavage via the natural sinus ostium, without ostial dilation.
Study: NCT02445352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
Study: NCT02157792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M6620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT03887793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VACs
Description: The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
Study: NCT02794597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHINE intervention group
Description: Includes all substance treatment services as well as the brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing: Sexual Health Initiative for Navigation and Empowerment (SHINE).
Study: NCT01316315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active
Description: A 5 mg single dose given intravenously via syringe pump over 1 minute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same as active
Study: NCT02195661

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: OTHER
Intervention: Chloral Hydrate
Study: NCT02157792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT02445352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Study: NCT02157792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT02445352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Study: NCT03220594

Intervention type: PROCEDURE
Intervention: hypogastric artery ligation
Description: hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation

Intervention type: PROCEDURE
Intervention: hypogastric artery ligation
Description: hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
Study: NCT04835935

Intervention type: OTHER
Intervention: microbiome pattern
Description: microbiome pattern in neonatal period

Intervention type: OTHER
Intervention: microbiome pattern
Description: microbiome pattern in neonatal period
Study: NCT02157792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT00263640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acaroid
Description: The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
Study: NCT02031081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: 2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 X 100mg tablets (encapsulated) by mouth once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
Study: NCT01376570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence-reinforcing contingency management intervention
Description: The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Performance Feedback intervention
Description: Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
Study: NCT02466074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: see arm description
Study: NCT02999854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell depleted HSCT from a related, haploidentical donor
Description: T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
Study: NCT01161433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtually delivered spirometry quality improvement program
Description: Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~1. Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~2. Case-based, interactive webinars; and~3. an Internet-based spirometry quality feedback reporting system.
Study: NCT02999854

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-cell replete HSCT from a related, haploidentical donor
Description: T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
Study: NCT03427528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers and Babies (FAB)
Description: The initial FAB session was delivered in person or by phone by the home visitor working with the mother, and lasted 30 min on average. Subsequent sessions were delivered, in-person, via text message with embedded links to online content, or a mix of both in-person and text messages, depending on the preference and availability of the father. Fathers received three to six text messages per FAB session.
Study: NCT01847157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermis anesthesia
Description: 15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Study: NCT03427528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MB 1-on-1 plus TXT
Description: Home visiting clients received the Mothers and Babies with -Text Messages intervention in person during regular scheduled home visits (i.e., MB 1-on-1 plus MB-TXT). After each in person session home visiting clients receive three messages to reinforce skill practice and remind them about their personal projects.
Study: NCT02912832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBDx
Description: The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
Study: NCT04615429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Administration of one single dose of allogenic Mesenchymal stromal cells
Study: NCT03512782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARDIOENF
Description: The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.